• NICE backs restricted use of Ondexxya pharmatimes
    April 07, 2021
    NHS cost regulators have backed funding for Alexion's Ondexxya (andexanet alfa) to reverse anticoagulation of the direct factor Xa (FXa) inhibitors apixaban or rivaroxaban in adults who experience a life-threatening or uncontrolled bleed in the ...
  • NICE backs Portola's Ondexxya pharmatimes
    September 14, 2020
    The National Institute for Health and Care Excellence (NICE) has published the outcome of an appraisal consultation document backing NHS funds for restricted use of Portola's Ondexxya (andexanet alfa) as an option for reversing anticoagulation ...
PharmaSources Customer Service